Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$73.21
+0.6%
$74.29
$60.01
$85.39
$9.41B0.871.09 million shs824,051 shs
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$26.18
+0.8%
$26.99
$25.00
$34.53
$2.35B1.061.02 million shs471,481 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$124.25
+6.1%
$126.18
$55.25
$159.89
$11.67B0.94985,086 shs1.50 million shs
Teleflex Incorporated stock logo
TFX
Teleflex
$211.17
+0.0%
$223.09
$177.63
$276.43
$9.95B1.11259,561 shs201,415 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Henry Schein, Inc. stock logo
HSIC
Henry Schein
+1.00%+2.16%-0.49%-0.68%-14.47%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
+0.23%+1.33%-4.73%-12.94%-4.84%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
+0.14%-0.14%-8.17%-2.58%-7.55%
Teleflex Incorporated stock logo
TFX
Teleflex
+1.89%+0.48%-4.42%-12.72%-21.59%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Henry Schein, Inc. stock logo
HSIC
Henry Schein
4.6814 of 5 stars
3.24.00.03.42.72.52.5
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
4.5241 of 5 stars
3.15.03.31.71.11.71.9
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
4.875 of 5 stars
4.44.00.04.21.92.51.9
Teleflex Incorporated stock logo
TFX
Teleflex
4.8262 of 5 stars
3.33.01.73.92.92.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Henry Schein, Inc. stock logo
HSIC
Henry Schein
2.36
Hold$81.0910.76% Upside
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
2.29
Hold$33.1126.47% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.80
Moderate Buy$158.3827.46% Upside
Teleflex Incorporated stock logo
TFX
Teleflex
2.60
Moderate Buy$267.5026.68% Upside

Current Analyst Ratings

Latest HSIC, PDCO, TFX, and SRPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/6/2024
Henry Schein, Inc. stock logo
HSIC
Henry Schein
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$82.00 ➝ $88.00
3/6/2024
Henry Schein, Inc. stock logo
HSIC
Henry Schein
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$74.00 ➝ $81.00
3/6/2024
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$31.00 ➝ $30.00
3/1/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$164.00 ➝ $167.00
2/29/2024
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$34.00 ➝ $28.00
2/29/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$128.00
2/29/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$151.00 ➝ $157.00
2/29/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$224.00
2/29/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$160.00 ➝ $172.00
2/29/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$141.00 ➝ $185.00
2/29/2024
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$169.00 ➝ $166.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$12.34B0.76$6.79 per share10.78$33.01 per share2.22
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$6.47B0.36$3.31 per share7.91$11.45 per share2.29
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.24B9.38N/AN/A$9.19 per share13.52
Teleflex Incorporated stock logo
TFX
Teleflex
$2.97B3.34$19.18 per share11.01$94.49 per share2.23

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$416M$3.1523.2413.141.793.37%14.03%6.22%5/7/2024 (Confirmed)
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$207.56M$2.0312.9010.561.362.95%20.98%7.70%6/19/2024 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$535.98M-$6.12N/A15.61N/A-43.11%-18.97%-4.65%5/7/2024 (Estimated)
Teleflex Incorporated stock logo
TFX
Teleflex
$356.33M$7.5328.0413.891.9811.98%14.98%8.87%5/2/2024 (Confirmed)

Latest HSIC, PDCO, TFX, and SRPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$0.99N/A-$0.99N/AN/AN/A  
5/2/2024N/A
Teleflex Incorporated stock logo
TFX
Teleflex
$3.07N/A-$3.07N/AN/AN/A  
2/28/2024Q3 2024
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$0.60$0.59-$0.01$0.66$1.63 billion$1.62 billion      
2/28/2024Q4 23
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$0.03$0.47+$0.50$0.47$387.18 million$396.80 million    
2/27/202412/31/2023
Henry Schein, Inc. stock logo
HSIC
Henry Schein
$0.70$0.66-$0.04$1.19$3.00 billion$3.02 billion      
2/22/2024Q4 23
Teleflex Incorporated stock logo
TFX
Teleflex
$3.26$3.38+$0.12$6.10$769.01 million$773.90 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Henry Schein, Inc. stock logo
HSIC
Henry Schein
N/AN/AN/AN/AN/A
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
$1.043.97%N/A51.23%N/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
Teleflex Incorporated stock logo
TFX
Teleflex
$1.360.64%N/A18.06%N/A

Latest HSIC, PDCO, TFX, and SRPT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/11/2024
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
Quarterly$0.263.86%4/18/20244/19/20245/3/2024
2/22/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Quarterly$0.340.57%2/29/20243/1/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Henry Schein, Inc. stock logo
HSIC
Henry Schein
0.45
1.67
1.00
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
0.46
1.43
0.72
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1.32
3.95
3.45
Teleflex Incorporated stock logo
TFX
Teleflex
0.39
2.32
1.29

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Henry Schein, Inc. stock logo
HSIC
Henry Schein
96.62%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
85.43%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%
Teleflex Incorporated stock logo
TFX
Teleflex
95.62%

Insider Ownership

CompanyInsider Ownership
Henry Schein, Inc. stock logo
HSIC
Henry Schein
1.14%
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
1.50%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7.40%
Teleflex Incorporated stock logo
TFX
Teleflex
1.43%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Henry Schein, Inc. stock logo
HSIC
Henry Schein
25,000128.48 million127.02 millionOptionable
Patterson Companies, Inc. stock logo
PDCO
Patterson Companies
7,60089.59 million88.25 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,31493.90 million86.95 millionOptionable
Teleflex Incorporated stock logo
TFX
Teleflex
14,50047.10 million46.43 millionOptionable

HSIC, PDCO, TFX, and SRPT Headlines

SourceHeadline
Teleflex Incorporated (NYSE:TFX) Shares Sold by Mackenzie Financial CorpTeleflex Incorporated (NYSE:TFX) Shares Sold by Mackenzie Financial Corp
marketbeat.com - April 23 at 5:11 AM
Shareholders in Teleflex (NYSE:TFX) are in the red if they invested three years agoShareholders in Teleflex (NYSE:TFX) are in the red if they invested three years ago
finance.yahoo.com - April 22 at 7:44 AM
Teleflex Incorporated (NYSE:TFX) Shares Purchased by Zurcher Kantonalbank Zurich CantonalbankTeleflex Incorporated (NYSE:TFX) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank
marketbeat.com - April 22 at 5:47 AM
Teleflex Incorporated (NYSE:TFX) Shares Purchased by Cooke & Bieler LPTeleflex Incorporated (NYSE:TFX) Shares Purchased by Cooke & Bieler LP
marketbeat.com - April 21 at 7:35 AM
Allspring Global Investments Holdings LLC Buys 16,110 Shares of Teleflex Incorporated (NYSE:TFX)Allspring Global Investments Holdings LLC Buys 16,110 Shares of Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 19 at 4:50 AM
Teleflex Incorporated (NYSE:TFX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesTeleflex Incorporated (NYSE:TFX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
americanbankingnews.com - April 19 at 2:34 AM
Which Is a Better Investment, Rxsight Inc or Teleflex Inc Stock?Which Is a Better Investment, Rxsight Inc or Teleflex Inc Stock?
aaii.com - April 18 at 1:09 PM
Teleflex Announces First Quarter 2024 Earnings Conference Call InformationTeleflex Announces First Quarter 2024 Earnings Conference Call Information
globenewswire.com - April 18 at 6:30 AM
Cerity Partners LLC Buys Shares of 13,175 Teleflex Incorporated (NYSE:TFX)Cerity Partners LLC Buys Shares of 13,175 Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 18 at 5:40 AM
Raymond James Financial Services Advisors Inc. Trims Holdings in Teleflex Incorporated (NYSE:TFX)Raymond James Financial Services Advisors Inc. Trims Holdings in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 15 at 4:27 AM
DekaBank Deutsche Girozentrale Has $1.74 Million Position in Teleflex Incorporated (NYSE:TFX)DekaBank Deutsche Girozentrale Has $1.74 Million Position in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 14 at 5:19 AM
Guru Fundamental Report for TFX - Benjamin GrahamGuru Fundamental Report for TFX - Benjamin Graham
nasdaq.com - April 13 at 9:49 AM
Sequoia Financial Advisors LLC Makes New $1.72 Million Investment in Teleflex Incorporated (NYSE:TFX)Sequoia Financial Advisors LLC Makes New $1.72 Million Investment in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 13 at 6:40 AM
Teleflex Incorporated (NYSE:TFX) Shares Sold by Lawson Kroeker Investment Management Inc. NETeleflex Incorporated (NYSE:TFX) Shares Sold by Lawson Kroeker Investment Management Inc. NE
marketbeat.com - April 11 at 3:56 PM
Villere ST Denis J & Co. LLC Reduces Stock Position in Teleflex Incorporated (NYSE:TFX)Villere ST Denis J & Co. LLC Reduces Stock Position in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 8 at 12:23 PM
Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATCTeleflex (TFX) Debuts the New Unified UroLift 2 System With ATC
zacks.com - April 8 at 9:21 AM
Teleflex Unveils Advanced Tissue Control for UroLift 2 System, Revolutionizing BPH TreatmentTeleflex Unveils Advanced Tissue Control for UroLift 2 System, Revolutionizing BPH Treatment
msn.com - April 5 at 10:39 AM
Boston Trust Walden Corp Has $56.82 Million Holdings in Teleflex Incorporated (NYSE:TFX)Boston Trust Walden Corp Has $56.82 Million Holdings in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - April 4 at 11:30 PM
Teleflex catheterization kit recall linked to 10 injuries, 1 deathTeleflex catheterization kit recall linked to 10 injuries, 1 death
medtechdive.com - April 4 at 2:34 PM
Research Analysts Issue Forecasts for Teleflex Incorporateds FY2025 Earnings (NYSE:TFX)Research Analysts Issue Forecasts for Teleflex Incorporated's FY2025 Earnings (NYSE:TFX)
marketbeat.com - April 3 at 6:31 AM
Teleflex launches UroLift 2 with advanced tissue controlTeleflex launches UroLift 2 with advanced tissue control
massdevice.com - April 2 at 5:35 PM
Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate TypesTeleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types
finance.yahoo.com - April 2 at 8:41 AM
Teleflex Sets Ambitious Climate Targets, Validated by Science Based Targets InitiativeTeleflex Sets Ambitious Climate Targets, Validated by Science Based Targets Initiative
msn.com - April 1 at 12:54 AM
AMI Asset Management Corp Has $18.86 Million Stock Position in Teleflex Incorporated (NYSE:TFX)AMI Asset Management Corp Has $18.86 Million Stock Position in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - March 30 at 11:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Henry Schein logo

Henry Schein

NASDAQ:HSIC
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Patterson Companies logo

Patterson Companies

NASDAQ:PDCO
Patterson Companies, Inc. engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems. It also provides a range of related services comprising software and design services, maintenance and repair, and equipment financing. The Animal Health segment distributes biologicals, pharmaceuticals, vaccines, parasiticides, diagnostics, prescription and non-prescription diets, nutritional's, consumable supplies, equipment, and software, as well as value-added services. This segment also provides private label portfolio of products to veterinarians, producers, and retailers under the Aspen, First Companion, and Patterson Veterinary brands. The Corporate segment offers customer financing services; and sells other miscellaneous products. It serves dentists, laboratories, institutions, other healthcare professionals, veterinarians, other animal health professionals, production animal operators, and animal health product retailers. The company was formerly known as Patterson Dental Company and changed its name to Patterson Companies, Inc. in June 2004. Patterson Companies, Inc. was founded in 1877 and is headquartered in Saint Paul, Minnesota.
Sarepta Therapeutics logo

Sarepta Therapeutics

NASDAQ:SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Teleflex logo

Teleflex

NYSE:TFX
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.